Form 8-K EAGLE PHARMACEUTICALS, For: Feb 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Eagle Pharmaceuticals (EGRX) to reduce current workforce by approximately 36%
February 29, 2024 8:14 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) disclosed:
On February 28, 2024, the Board of Directors of Eagle Pharmaceuticals, Inc. (the Company) approved a plan designed to improve operational efficiencies and realign the Companys sales and marketing expenditures (the Realignment Plan).
The Realignment Plan is expected to reduce the Companys current workforce by approximately 36%. Substantially all affected employees are currently dedicated to or primarily supporting the commercialization of Byfavo, Barhemsys and Ryanodex. The Company intends to utilize a reduced team dedicated to these products in addition to resources from the... More
